All products / DC7324
Amuvatinib (MP-470)
Pack sizes and prices
| Pack size | Price |
|---|---|
| 100 mg | $450 USDRequest a quote → |
| 250 mg | $800 USDRequest a quote → |
| 1 g | $1,500 USDRequest a quote → |
| 10 mM * 1 mL in DMSO | $150 USDRequest a quote → |
In stock. Contact our team for lead time, shipping and final quotation.
Product overview
Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively.
For research use only. Results depend on experimental conditions and do not constitute a performance guarantee.
Identity and specifications
| Catalog number | DC7324 |
|---|---|
| Product name | Amuvatinib (MP-470) |
| CAS | 850879-09-3 |
| Molecular formula | C23H21N5O3S |
| Molecular weight | 447.5095 |
| Purity | >98% |
| SMILES | S=C(N([H])C([H])([H])C1C([H])=C([H])C2=C(C=1[H])OC([H])([H])O2)N1C([H])([H])C([H])([H])N(C2C3=C(C4=C([H])C([H])=C([H])C([H])=C4O3)N=C([H])N=2)C([H])([H])C1([H])[H] |
Source-listed specifications; the batch COA applies.
Source and product documents
The supplier source is linked below. Contact us for COA, SDS and batch-specific documents.
DC Chemicals — Amuvatinib (MP-470) (DC7324)Source references
[1]. Bearss DJ, et al. US Patent, US/2008/0226747. [2]. Hurley LH, et al. World Patent, WO/2005/037825. [3]. Mahadevan D, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene, 2007, 26(27), 3909-3919. [4]. Qi W, et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer, 2009, 9, 142.
